MedTrace Logo

Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies

NCT04893239 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

This is a Phase 1, single-site, open label, exploratory study to assess delivery of LMN-201 components via enteric capsules in the gut of individuals with ostomies.

Conditions

  • C. Diff. Infections

Interventions

BIOLOGICAL

LMN-201 Anti-toxin B VHH-1

Components of LMN-201

BIOLOGICAL

LMN-201 Anti-toxin B VHH-2

Components of LMN-201

BIOLOGICAL

LMN-201 Anti-toxin B VHH-3

Components of LMN-201

BIOLOGICAL

LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3

Components of LMN-201

Sponsors & Collaborators

  • Lumen Bioscience, Inc.

    lead INDUSTRY

Principal Investigators

  • Carl Mason · Lumen Bioscience, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-18
Primary Completion
2022-02-23
Completion
2022-02-23

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893239 on ClinicalTrials.gov